US FDA’s Patent ‘Concerns’ Include Thickets, Product Hopping, And Evergreening
• By M. Nielsen Hobbs
With a report due to Congress in January, Orange Book patent issues may find their way into user fee reauthorization legislation next year. • Source: Nielsen Hobbs
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
